Asuragen Shares Their Molecular Testing Capabilities for Fragile X

Stela Filipovic-Sadic, a manager of Research & Development at Asuragen, presented Asuragen’s molecular testing capabilities for FMR1 and Fragile X, and showed how new technologies drive progress in the field. Asuragen has been a part of the Fragile X community for years. Their tests have been used to help patients, clinicians, and researchers aid in diagnosis, screen potential carriers, stratify the risk of Fragile X being passed onto the next generation, and connect patients to new therapies.

Check out the Behind the Mystery of Fragile X Syndrome segment sponsored by Asuragen.